Alexandru Călin Grigorescu
Carol Davila University of Medicine and Pharmacy · 187 works · 2,079 citations · h-index 9
Top works
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
- ESMO takes a stand on supportive and palliative care
- Evidence for immune defects in breast and lung cancer patients
- Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial
- Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO)
- Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
- Underlying Ciliary Body Uveal Melanoma in a Patient with Chronic Lymphocytic Leukemia Presenting for Hyphema
- Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest
- Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting (CINV): Results of the Nausea/Emesis Registry in Oncology (NERO).
- A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC)
- Pathological and Molecular Diagnosis of Uveal Melanoma
- Synchronous Breast and Colorectal Malignant Tumors—A Systematic Review
- Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients.
- Pemetrexed in Third and Fourth Line Chemotherapy for Non Squamous Non Small-Cell Lung Cancer
- B3-06: Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)
- Faculty Opinions recommendation of Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
- How specific molecular‑targeted agents can make obsolete a ‘one size fits all’ approach in EGFR‑mutated NSCLC treatment (Review)
- The Effects of Oncological Treatment on Redox Balance in Patients with Uveal Melanoma
- The Importance of the Nutritional Factor and the Stage of the Disease in Postoperative Fistula in Patients with Gastric Cancer